References


First Primary Melanoma Risk

Development and external validation of a melanoma risk prediction model based on self-assessed risk factors.

Vuong K, Armstrong BK, Weiderpass E, Lund E, Adami H, Veierod MB, Barrett JH, Davies JR, Bishop DT, Whiteman DC, Olsen CM, Hopper JL, Mann GJ, Cust AE, McGeechan K, Australian Melanoma Family Study Investigators. JAMA Dermatol. 2016 Aug 1;152(8):889-96. doi: 10.1001/jamadermatol.2016.0939. PMID: 27276088

Link to Publication

Sentinel Node Metastasis Risk

Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Austalia nomogram.

Lo SN, Ma J, Scolyer RA, Haydu LE, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Ch’ng S, Mann GJ, Gershenwald JE, Thompson JF, Varey AHR. J Clin Oncol. 2020 Jun 12:JCO1902362. doi: 10.1200/JCO.19.02362. Online ahead of print. PMID: 32530761

Link to Publication
Predicting sentinel node positivity in melanoma patients: external validation of a risk‐prediction calculator (the MIA nomogram) using a large European population‐based patient cohort

Mary-Ann El Sharouni, Alexander H. R. Varey, Arjen J. Witkamp, Tasnia Ahmed, Vigfús Sigurdsson, Paul J. van Diest, Richard A. Scolyer, John F. Thompson, Serigne N. Lo, Carla H. van Gils. British Journal of Dermatology [Epub ahead of print]

Link to Publication

Subsequent Primary Melanoma Risk

A risk prediction model for the development of subsequent primary melanoma in a population-based cohort.

Cust AE, Badcock C, Smith J, Thomas NE, Haydu LE, Armstrong BK, Law MH, Thompson JF, Kanetsky PA, Begg CB, Shi Y, Kricker A, Orlow I, Sharma A, Yoo S, Leong SF, Berwick M, Ollila DW, Lo S. Br J Dermatol. 2020 May;182(5):1148-1157. doi: 10.1111/bjd.18524. PMID: 31520533

Link to Publication

Thin Melanoma Recurrence Risk

Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas

Mary-Ann El Sharouni, Tasnia Ahmed, Alexander H. R. Varey, Sjoerd G. Elias, Arjen J. Witkamp, Vigfús Sigurdsson, Karijn P. M. Suijkerbuijk, Paul J. van Diest, Richard A. Scolyer, Carla H. van Gils, John F. Thompson, Willeke A. M. Blokx, and Serigne N. Lo. J Clin Oncol

Link to Publication

Immunotherapy Outcomes Prediction

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P, Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM. J Clin Oncol. 2022 Feb 10:JCO2101701. doi: 10.1200/JCO.21.01701.

Link to Publication